HemaSphere (Apr 2023)

5589320 FOLLOW-UP RESULTS OF A PHASE 2 STUDY ASSESSING THE SAFETY AND EFFICACY OF MITAPIVAT TREATMENT, AN ORAL PYRUVATE KINASE ACTIVATOR, FOR UP TO 60 WEEKS IN SUBJECTS WITH SICKLE CELL DISEASE

  • M.J. van Dijk,
  • M.A.E. Rab,
  • B.A. van Oirschot,
  • J.F. Bos,
  • C. Derichs,
  • A.W. Rijneveld,
  • M.H. Cnossen,
  • E. Nur,
  • B.J. Biemond,
  • M. Bartels,
  • J.J.M. Jans,
  • W.W. van Solinge,
  • R.E.G. Schutgens,
  • R. van Wijk,
  • E.J. van Beers

DOI
https://doi.org/10.1097/01.HS9.0000928136.09596.24
Journal volume & issue
Vol. 7, no. S1
pp. 1 – 2

Abstract

Read online

No abstracts available.